Morgan Stanley
SABS icon

Morgan Stanley’s SAB Biotherapeutics SABS Stock Holding History

Morgan Stanley’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.6K Buy
13,750
+1,839
+15% +$6.84K ﹤0.01% 6485
2026
Q1 		$45.6K Buy
11,911
+7,649
+179% +$30.5K ﹤0.01% 6453
2025
Q4 		$15.9K Buy
4,262
+4,094
+2,437% +$13.5K ﹤0.01% 6766
2025
Q3 		$338 Hold
168
– – ﹤0.01% 7536
2025
Q2 		$295 Sell
168
-281
-63% -$465 ﹤0.01% 7521
2025
Q1 		$610 Sell
449
-150
-25% -$344 ﹤0.01% 7346
2024
Q4 		$2.27K Sell
599
-100
-14% -$329 ﹤0.01% 7176
2024
Q3 		$1.89K Hold
699
– – ﹤0.01% 7142
2024
Q2 		$2.17K Sell
699
-500
-42% -$1.83K ﹤0.01% 7052
2024
Q1 		$5.44K Sell
1,199
-1,102
-48% -$6.07K ﹤0.01% 6874
2023
Q4 		$15.8K Buy
2,301
+760
+49% +$6.37K ﹤0.01% 6731
2023
Q3 		$9.71K Sell
1,541
-190
-11% -$1.4K ﹤0.01% 6739
2023
Q2 		$14.4K Hold
1,731
– – ﹤0.01% 6672
2023
Q1 		$7.61K Buy
1,731
+10
+0.6% +$63 ﹤0.01% 6961
2022
Q4 		$10.2K Sell
1,721
-786
-31% -$7.18K ﹤0.01% 6928
2022
Q3 		$18K Buy
2,507
+32
+1% +$318 ﹤0.01% 6841
2022
Q2 		$36K Sell
2,475
-21
-0.8% -$441 ﹤0.01% 6760
2022
Q1 		$95K Sell
2,496
-728
-23% -$33.6K ﹤0.01% 6344
2021
Q4 		$252K Buy
+3,224
New +$302K ﹤0.01% 5941
2021
Q2 		– Sell
-13
Closed -$1K – 7792
2021
Q1 		$1K Buy
+13
New +$1.3K ﹤0.01% 7372

Other funds holding SABS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's SABS Position: Q2 2026 in Review

Morgan Stanley increased its SAB Biotherapeutics (SABS) stake by 15% in Q2 2026, buying an estimated $6.84K and bringing the position to 13,750 shares worth $53.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6485.

Morgan Stanley first reported a position in SABS in Q1 2021 and has held it in 20 quarters since. The position peaked at $252K in Q4 2021. 49 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Morgan Stanley held 13,750 shares of SAB Biotherapeutics worth $53.6K as of Q2 2026.
  • Morgan Stanley bought 1,839 SAB Biotherapeutics shares in Q2 2026, an estimated $6.84K.
  • SAB Biotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6485 holding.
  • Morgan Stanley first reported a position in SAB Biotherapeutics in Q1 2021 and has held it in 20 quarters since.
  • Morgan Stanley's SAB Biotherapeutics position peaked at $252K in Q4 2021.
  • 49 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.